Mingchen Health Co.,Ltd.'s (SZSE:002919) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mingchen Health Co.,Ltd.'s (SZSE:002919) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mingchen HealthLtd (SZSE:002919) has had a great run on the share market with its stock up by a significant 14% over the last month. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be paying attention to Mingchen HealthLtd's ROE today.
明晨健康有限公司(深圳證券交易所:002919)在股市上表現良好,其股票比上個月大幅上漲了14%。鑑於從長遠來看,市場會獎勵強勁的財務狀況,我們想知道在這種情況下是否如此。特別是,我們今天將關注明晨健康有限公司的投資回報率。
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.
股本回報率或投資回報率是用於評估公司管理層利用公司資本效率的關鍵指標。換句話說,它是衡量公司股東提供的資本回報率的盈利比率。
See our latest analysis for Mingchen HealthLtd
查看我們對 Mingchen HealthLtd 的最新分析
How To Calculate Return On Equity?
如何計算股本回報率?
The formula for ROE is:
ROE 的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回報率 = 淨利潤(來自持續經營)÷ 股東權益
So, based on the above formula, the ROE for Mingchen HealthLtd is:
因此,根據上述公式,Mingchen HealthLtd的投資回報率爲:
23% = CN¥210m ÷ CN¥905m (Based on the trailing twelve months to September 2023).
23% = 2.1億元人民幣 ¥9.05億元人民幣(基於截至2023年9月的過去十二個月)。
The 'return' is the profit over the last twelve months. One way to conceptualize this is that for each CN¥1 of shareholders' capital it has, the company made CN¥0.23 in profit.
“回報” 是過去十二個月的利潤。將其概念化的一種方法是,公司每擁有1元人民幣的股東資本,就能獲得0.23元人民幣的利潤。
What Has ROE Got To Do With Earnings Growth?
投資回報率與收益增長有什麼關係?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.
我們已經確定,投資回報率是衡量公司未來收益的有效利潤指標。我們現在需要評估公司再投資或 “保留” 了多少利潤以用於未來的增長,這樣我們就可以了解公司的增長潛力。一般而言,在其他條件相同的情況下,股本回報率和利潤保留率高的公司比不具備這些屬性的公司的增長率更高。
Mingchen HealthLtd's Earnings Growth And 23% ROE
Mingchen HealthLtd的收益增長和23%的投資回報率
Firstly, we acknowledge that Mingchen HealthLtd has a significantly high ROE. Second, a comparison with the average ROE reported by the industry of 11% also doesn't go unnoticed by us. So, the substantial 24% net income growth seen by Mingchen HealthLtd over the past five years isn't overly surprising.
首先,我們承認明晨健康有限公司的投資回報率非常高。其次,與該行業報告的平均投資回報率爲11%的比較也不會被我們忽視。因此,明晨健康有限公司在過去五年中實現了24%的淨收入大幅增長並不令人驚訝。
Next, on comparing with the industry net income growth, we found that Mingchen HealthLtd's growth is quite high when compared to the industry average growth of 4.4% in the same period, which is great to see.
接下來,與行業淨收入增長相比,我們發現明晨健康有限公司的增長與同期4.4%的行業平均增長率相比相當高,這真是太好了。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231130/0-4cd01d0bc9c5d7ffeaf7803bf1fb8c94-0-669a57f6f88fb69782defe1b49f86435.png/big)
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. If you're wondering about Mingchen HealthLtd's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.
爲公司附加價值的基礎在很大程度上與其收益增長息息相關。投資者接下來需要確定的是,預期的收益增長或缺乏收益是否已經包含在股價中。通過這樣做,他們將知道股票是走向清澈的藍色海水還是沼澤水域在等着呢。如果你想知道明晨健康有限公司的估值,可以看看這個衡量其與行業相比的市盈率指標。
Is Mingchen HealthLtd Making Efficient Use Of Its Profits?
Mingchen HealthLtd 是否在有效利用其利潤?
While the company did pay out a portion of its dividend in the past, it currently doesn't pay a dividend. This is likely what's driving the high earnings growth number discussed above.
儘管該公司過去確實支付了部分股息,但目前不支付股息。這可能是推動上述高收益增長數字的原因。
Summary
摘要
In total, we are pretty happy with Mingchen HealthLtd's performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. If the company continues to grow its earnings the way it has, that could have a positive impact on its share price given how earnings per share influence long-term share prices. Not to forget, share price outcomes are also dependent on the potential risks a company may face. So it is important for investors to be aware of the risks involved in the business. You can see the 1 risk we have identified for Mingchen HealthLtd by visiting our risks dashboard for free on our platform here.
總的來說,我們對明晨健康有限公司的表現非常滿意。具體而言,我們喜歡該公司以高回報率再投資其利潤的很大一部分。當然,這導致該公司的收益大幅增長。考慮到每股收益如何影響長期股價,如果該公司繼續以現有方式增長收益,這可能會對其股價產生積極影響。別忘了,股價結果還取決於公司可能面臨的潛在風險。因此,投資者必須意識到業務所涉及的風險。您可以訪問我們的 Mingchen HealthLtd 的 1 種風險 風險儀表板 在我們的平台上免費使用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。